EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 172 filers reported holding EAGLE PHARMACEUTICALS INC in Q3 2017. The put-call ratio across all filers is 0.91 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $108,000 | +3.8% | 2,255 | 0.0% | 0.01% | -12.5% |
| Q1 2020 | $104,000 | -23.0% | 2,255 | 0.0% | 0.01% | +14.3% |
| Q4 2019 | $135,000 | +19.5% | 2,255 | +13.3% | 0.01% | 0.0% |
| Q3 2019 | $113,000 | +1.8% | 1,990 | 0.0% | 0.01% | 0.0% |
| Q2 2019 | $111,000 | +12.1% | 1,990 | +1.7% | 0.01% | +16.7% |
| Q1 2019 | $99,000 | +13.8% | 1,957 | -9.3% | 0.01% | 0.0% |
| Q4 2018 | $87,000 | +14.5% | 2,157 | +97.9% | 0.01% | +50.0% |
| Q3 2018 | $76,000 | -21.6% | 1,090 | -15.3% | 0.00% | -33.3% |
| Q2 2018 | $97,000 | +42.6% | 1,287 | 0.0% | 0.01% | +50.0% |
| Q1 2018 | $68,000 | -1.4% | 1,287 | 0.0% | 0.00% | 0.0% |
| Q4 2017 | $69,000 | +7.8% | 1,287 | +20.4% | 0.00% | 0.0% |
| Q3 2017 | $64,000 | -5.9% | 1,069 | +24.9% | 0.00% | 0.0% |
| Q2 2017 | $68,000 | -4.2% | 856 | 0.0% | 0.00% | -20.0% |
| Q1 2017 | $71,000 | +153.6% | 856 | +140.4% | 0.01% | +150.0% |
| Q4 2016 | $28,000 | +12.0% | 356 | 0.0% | 0.00% | 0.0% |
| Q3 2016 | $25,000 | – | 356 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ProQuest Associates IV LLC | 3,652,284 | $302,920,000 | 91.10% |
| Hudson Executive Capital LP | 1,901,200 | $157,686,000 | 21.62% |
| JW Asset Management, LLC | 525,755 | $43,606,000 | 9.08% |
| Cormorant Asset Management, LP | 200,000 | $16,588,000 | 2.41% |
| Park West Asset Management LLC | 488,128 | $40,485,000 | 2.36% |
| Opaleye Management Inc. | 50,000 | $4,147,000 | 2.06% |
| Ranger Investment Management | 283,954 | $23,551,000 | 1.71% |
| Pier Capital, LLC | 74,732 | $6,198,000 | 1.06% |
| Bellevue Group AG | 67,700 | $5,615,000 | 0.75% |
| Orbimed Advisors | 671,000 | $55,653,000 | 0.63% |